HLAG Protein (Tetramer) (PE,HLA-G)

N° du produit ABIN7274819

Détail du produit

Antigène: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Type de proteíne: Recombinant

Attributs du protein: Tetramer

Origine: Humain

Source: HEK-293 Cells

Purification/Conjugué: Cette HLAG protéine est marqué à la PE,HLA-G.

Fonction: PE-Labeled Human HLA-G & B2M & Peptide (RIIPRHLQL) Tetramer Protein

Séquence: Gly25-Thr305 (HLA-G), Ile21-Met119 (B2M) and RIIPRHLQL peptide

Specificité: Uni-Prot: P17693-1 (HLA-G), P61769 (B2M), RIIPRHLQL

Attributs du produit: Recombinant PE-Labeled Human HLA-G & B2M & Peptide (RIIPRHLQL) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. PE-Labeled Human HLA-G & B2M & Peptide (RIIPRHLQL) Tetramer is assembled by biotinylated monomer and PE-labeled streptavidin.It contains Gly25-Thr305 (HLA-G), Ile21-Met119 (B2M) and RIIPRHLQL peptide.

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1EU per μg by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Supplied as 0.22μm filtered solution in PBS, 0.2 % BSA ( pH 7.4).

Stock: -80 °C

Stockage commentaire: Valid for 6 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Date de péremption: 12 months

Détail du antigène

Antigène: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Autre désignation: HLA-G (HLAG Produits)

Synonymes: MHC-G Protein, B-F Protein, B-F-S04 Protein, B-F-S05 Protein, B-F-S06 Protein, B-F-S07 Protein, B-FI Protein, B-FIV Protein, BF2 Protein, BFa2 Protein, BFw-03 Protein, BFw-05 Protein, BFz-01 Protein, major histocompatibility complex, class I, G Protein, MHC BF1 class I Protein, HLA-G Protein, BF1 Protein

Sujet: HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response